GEMINA LABS ANNOUNCES COMPLETION OF SIGNIFICANT DEVELOPMENT STEP FOR ITS SARS-COV-2 RAPID TEST

February 3, 2022

GEMINA LABORATORIES LTD. 

News Release 

February 3, 2022 

GEMINA LABS ANNOUNCES COMPLETION OF SIGNIFICANT DEVELOPMENT STEP FOR ITS SARS-COV-2 RAPID TEST 

February 3, 2022, Vancouver, British Columbia: Gemina Laboratories Ltd. (CSE: GLAB) (FRA:8I7) (the  “Company” or “Gemina”) is pleased to provide an update on its current activities related to the  development of its first rapid diagnostic test targeting the SARS CoV-2 antigen, using the Company’s  patented breakthrough chemistry platform. Following the previously announced prototype design freeze  for use in saliva and the transfer of the prototype to International Point of Care (“IPOC”), the company is  pleased to announce the completion of another important milestone, namely: design freeze for shallow  nasal swab testing. From a regulatory perspective, nasal swabs have become the leading method for large  scale rapid testing globally. 

Gemina’s team previously announced that their SARS-CoV-2 test has already demonstrated outstanding  performance in a lab setting. Independent laboratory results with Gemina’s prototype SARS-CoV-2 rapid  antigen test indicated the company was able to reliably detect recombinant SARS-CoV-2 nucleocapsid in  saliva and nasal fluid samples with significantly higher sensitivity when compared with a panel of seven  leading commercial rapid antigen tests (Lancet – Corman, et al. 2021). 

This latest milestone indicates that the performance of this finalized test design with inactivated virus and  with real patient samples is sufficient evidence to initiate the production of three feasibility lots (of 3,500  rapid tests per lot) which will undergo third party performance evaluations. The test has been optimized  for use with anterior (shallow) nasal swab samplesin response to market and regulatory signals. Detection  of inactivated virus in artificial nasal fluid at clinically relevant concentrations has been independently  confirmed by an external laboratory using the Gemina test. A second independent evaluation is scheduled  to occur within the next week. The test has also been run against nasal fluid provided from a panel of  COVID-negative volunteers and shown to exhibit no non-specific binding (no false positive signals).  

In the following three months, the test will be taken through a series of sensitivity and specificity trials in  advance of feasibility lot production, including evaluation of test specificity against seasonal  coronaviruses. Three feasibility lots will then be tested to confirm sensitivity, usability, shelf stability, and  lot-to-lot consistency with contrived inactivated virus samples. The test will then be subjected to an  external performance evaluation with retrospective patient samples as part of the compilation of the data  pack required to support regulatory submissions. Successful completion of these performance evaluations  is a critical step towards manufacturing scale-up and allows the company to advance commercialization  efforts through distribution and licensing agreements. 

“Our partnership with IPOC to support the advancement of our first COVID diagnostic test is proving  successful, and we continue to see encouraging, clinically relevant results from the first product  development programme to emerge from our broad and robust technology platform,” commented Rob  Greene, Founder and CTO of Gemina Labs. “The resurgence of the Omicron variant in recent months  makes it clear that we may need high performance rapid tests for years to come, in order to detect and 

control the spread of COVID-19. Today’s milestone provides another layer of evidence that we are  developing the pandemic response platform and product that we set out to achieve.” 

On Behalf of the Board of Directors 

John Davies 

CEO 

Gemina Laboratories Ltd. 

About Gemina Laboratories Ltd. 

Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary  chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Our technology drives testing platforms that are fast, affordable and accurate, and  easily self-administered. Our development pipeline includes platforms for the rapid testing of COVID-19,  influenza and other viruses. Additional information on the Company can be found at  www.geminalabs.com. 

About IPOC 

International Point of Care is a leading Canadian company that develops, manufactures and supplies  unique biological reagents, raw materials, and lateral flow components for the in-vitro diagnostic industry  and the research and development community. 

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined  in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy  of this Release. 

Forward Looking Statements 

This news release includes forward-looking information and statements, which may include, but are not  limited to, information and statements regarding or inferring the future business, operations, financial  performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company.  Such statements include statements regarding the anticipated terms of any proposed transaction or  engagement. Information and statements which are not purely historical fact are forward-looking  statements. Forward-looking information and statements involve and are subject to assumptions and  known and unknown risks, uncertainties, and other factors which may cause actual events, results,  performance, or achievements of the Company to be materially different from future events, results,  performance, and achievements expressed or implied by forward-looking information and statements  herein. Although the Company believes that any forward-looking information and statements herein are  reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such  information and statements, there can be no assurance that any such forward-looking information and  statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation  of such risks and uncertainties and should not place undue reliance upon such forward-looking  information and statements. Furthermore, the Company is presently unable to fully quantify the impact  that the Covid-19 pandemic will have on its operations and recognizes that certain eventualities may  affect planned or assumed performance moving forward. As such, any forward-looking information and  statements herein are made as of the date hereof, and except as required by applicable laws, the 

Company assumes no obligation and disclaims any intention to update or revise any forward-looking  information and statements herein or to update the reasons that actual events or results could or do differ  from those projected in any forward looking information and statements herein, whether as a result of  new information, future events or results, or otherwise, except as required by applicable laws.  

For more information regrading the Company, please contact: 

James Tansey 

Telephone: 604-562-4546  

Email: investor@geminalabs.com

Receive Company Updates
Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.

Press and Updates

AGM DOCUMENTATION

December 20, 2022
Read More

GEMINA LABS APPOINTS DR MICHAEL SHANNON AS CHAIR OF CLINICAL ADVISORY BOARD

December 20, 2022
Read More

GEMINA LABS ANNOUNCES RESEARCH COLLABORATION ON NEXT GENERATION BIOSENSORS

December 19, 2022
Read More

Enter Your Email To Sign Up For Campaign Updates. 

Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.